Genica Genetics of Cancer
Oncology

Genetics of Cancer

Genetic testing for hereditary and somatic cancers is the basis for proper diagnosis and treatment of affected patients. It can help families better understand their risk of cancer and to decide if they should get tested or learn about how to lower their risk of cancer. Genetic testing helps detecting cancer earlier when treatment is most likely to work better.

Some families may be at increased risk of developing certain types of cancer due to inherited gene mutations. Genetic analysis can determine if you are at increased risk of developing cancer and suggest an appropriate strategy for prevention or monitoring.

Thanks to genetic tests, doctors can choose the right therapeutic options. Some cancers, for example, will respond differently to treatment by particular classes of drugs, depending on the presence or absence of certain genetic variants. Testing and treating tumors in such a way is also known as personalized medicine.

GENICA tests a wide range of genetic variants, enabling early prevention, cancer diagnosis, prognosis, treatment choice and post-therapeutic monitoring of the patient. Our set of oncological tests is extensive and is continuously updated. Contact us if you cannot find a specific test you need.

Genetic Tests for Cancer Detection and Prevention

Hereditary Cancer Panel – Women

The test detects mutations in 62 genes associated with hereditary cancer in women. Genetic testing for hereditary and somatic cancers is the basis for proper diagnosis and treatment in affected patients. They are also indispensable in the early prevention of their relatives, who are carriers of genetic mutations associated with the risk of developing cancer. We can guide doctors in choosing the right therapeutic options with the help of genetic tests for detecting and preventing cancer.

GENIKA Lab analyses a wide range of genetic variants, enabling early prevention, cancer diagnosis, prognosis, treatment choice and post-therapeutic monitoring of the patient.

Diagnostic Range: APC, ATM, AXIN2, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, EPCAM, EXT1, EXT2, FH, FLCN, GALNT12, HOXB13, KIT, MAX, MEN1, MET, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, NTRK1, PALB2, PDGFRA, PMS1, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHD, SDHC, SMAD4, SMARCA4, STK11, TMEM127, TP53, VHL.

Diagnostic Method: New Generation Sequencing

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 3,200

Clinical application

 Hereditary carcinoma 

Genetic Tests for Cancer Detection and Prevention

Hereditary Cancer Panel - Men

The test detects mutations in 62 genes associated with hereditary cancer in men. Genetic testing for hereditary and somatic cancers is the basis for proper diagnosis and treatment in affected patients. They are also indispensable in the early prevention of their relatives, who are carriers of genetic mutations associated with the risk of developing cancer. We can guide doctors in choosing the right therapeutic options with the help of genetic tests for detecting and preventing cancer.

GENICA Lab analyses a wide range of genetic variants, enabling early prevention, cancer diagnosis, prognosis, treatment choice and post-therapeutic monitoring of the patient.

Diagnostic Range: APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, EPCAM, EXT1, EXT2, FH, FLCN, MAX, MEN1, MET, MLH1, MLH3, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NTRK1, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RB1, RET, SDHAF2, SDHB, SDHD, SDHC, SMAD4, STK11, TMEM127, TP53, VHL, RAD51D, EPCAM, SMARCA4, KIT, PDGFRA, SDHA, BLM, GALNT12, MSH3, POLD1, POLE, HOXB13, NTHL1

Diagnostic Method: New generation sequencing

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 3,200

Clinical application

 Hereditary carcinoma 

Sexually Transmitted Infections Associated with the Risk of Cancer

Cervical Cancer

 Cervical cancer is the second most common cancer globally among women between the ages of 20 and 55. It is caused by the human papillomavirus (HPV). Cervical cancer is the final stage of untreated HPV infection, characterized by the continuing presence of HPV and detected by repeated DNA testing of cervical samples. HPV infection is primarily sexually transmitted and usually occurs without clinical signs or symptoms.

The process from HPV infection to cancer is slow. This makes the initiating infections and the pre-disease lesions treatable with regular prophylaxis, thus preventing the development of cervical cancer.

Up to 93% of cervical cancers are preventable with GENICA’s diagnostic solutions. READ MORE

Diagnostic Range: HPV from 12 to 33 types

Diagnostic Method: PCR Assay

Research Material: Cervical specimen

Results within: 1-5 business days

Fee: BGN 66 - BGN 167 depending on the test selected

Clinical application

Cervical dysplasia; Cervical cancer; Oral cancer; Cancer of the vulva and vagina; Penile cancer; Anal cancer; Genital warts 

Download Our Brochure

Download Our Brochure

BRCA1 / BRCA2 Panel

Breast Cancer

This test detects mutations associated with breast cancer.

Diagnostic Range: BRCA1, BRCA2

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800

Clinical application

Breast Cancer

Cancerous Diseases

Gynecologic Oncology

A group of DNA tests associated with gynecologic cancers, including cervical cancer (SEE MORE), endometrial cancer, ovarian cancer, breast cancer.

Diagnostic Range: Human papillomavirus (HPV) associated with cervical cancer; MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, PTEN, MUTYH associated with hereditary endometrial carcinoma; BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMAR HOXB13 associated with ovarian and breast cancer

Diagnostic Method: Genetic analysis

Research Material: Cervical specimen / Biopsy material / Venous blood

Results within: 5-20 business days for various analyzes

Fee: From BGN 48 to BGN 1,800 for various analyzes

Clinical application

Cervical cancer; Endometrial cancer; Ovarian cancer; Breast cancer

Download Our Brochure

Genetic Tests for Hereditary Cancers

Oncoendocrinology

This test detects mutations associated with hereditary pancreatic cancer, multiple endocrine neoplasia, hereditary thyroid carcinoma, hereditary parathyroid carcinoma.

Diagnostic Range: BRCA2, PALB2, MEN1, RET, CDKN1B, RET, NTRK1, CDC73, MEN 1

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800 per disease tested

Used in

Pancreatic cancer; Thyroid cancer; Parathyroid cancer; Multiple endocrine neoplasia

Mutations in the IDH1 / IDH2 Genes

Oncomutations

The pharmacogenetics of cancer identifies patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. 

There are significant differences between the pharmacogenomics of cancer and other diseases.

Diagnostic Range: IDH1/IDH2

Diagnostic Method: Sanger sequencing/ RFLP

Research Material: Venous blood

Results within: 10 business days

Fee: BGN 150

Clinical application

Personalized therapy

Genetic Mutations Associated with the Risk of Developing Cancer

Hereditary Melanoma

This test detects mutations associated with the development of melanoma.

Diagnostic Range: CDKN2A, CDK4

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800

Clinical application

Melanoma

Cancerous Diseases

Hereditary Stomach Cancer

This test detects mutations associated with stomach cancer.

Diagnostic Range: CDH1, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, BMPR1A, SMAD4, STK11, TP53

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800

Clinical application

Stomach cancer

Genetic Mutations Associated with the Risk of Developing Cancer

Hereditary Colon Cancer

This test detects mutations associated with colon cancer.

Diagnostic Range: APC, AXIN2, EPCAM, MLH1, MLH3, MSH2, MSH6, MUTYH, PMS1, PMS2, STK11, PTEN, SMAD4, BMPR1A, ATM, BLM, CHEK2, GALNT12, MSH3, NTHL1, POLD1, POLE, TP53

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800

Clinical application

Colon cancer

Genetic Mutations Associated with the Risk of Developing Cancer

Hereditary Prostate Cancer

This test detects mutations associated with prostate cancer.

Diagnostic Range: BRCA1, BRCA2, CHEK2, HOXB13, MSH2, MSH6, PMS2, MLH1, ATM, BRIP1, PALB2

Diagnostic Method: NGS

Research Material: Venous Blood

Results within: 20 business days

Fee: BGN 1,800

Clinical application

Prostate cancer

Genetic Tests for Hereditary Cancers

Rare Hereditary Carcinomas

This test detects mutations associated with chondrosarcoma, retinoblastoma, familial paraganglioma, pheochromocytoma, neurofibromatosis 2, hereditary renal cell carcinoma.

Diagnostic Range: EXT1, EXT2 (Chondrosarcoma); RB1 (Retinoblastoma), SDHB, SDHC, SDHD, SDHAF2, VHL (Hereditary paraganglioma), SDHAF2, SDHB, SDHC, SDHD, RET, VHL, MAX, NF1, TMEM127 (Pheochromocytoma), NF1, NF2 (Neurofibromatosis 2), VHL, MET, FH, FLCN (Hereditary kidney cancer)

Diagnostic Method: NGS

Research Material: Venous blood

Results within: 20 business days

Fee: BGN 1,800 per disease tested

Clinical application

Chondrosarcoma; Retinoblastoma; Hereditary paraganglioma; Pheochromocytoma; Neurofibromatosis 2; Hereditary kidney cancer

Hypermethylation of the MGMT Promoter Region

MGMT Hypermethylation

The pharmacogenetics of cancer identifies patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. There are significant differences between the pharmacogenomics of cancer and other diseases.

Diagnostic Range: Hypermethylation of the MGMT promoter region

Diagnostic Method: Sanger sequencing/ RFLP

Research Material: Venous blood

Results within: 10 business days

Fee: BGN 270

Clinical application

Personalized therapy